¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20
±³À°ÀÏÀÚ : 2022-05-20
±³À°Àå¼Ò : ¼­¿ï·Ôµ¥È£ÅÚ(¼Ò°øµ¿)  
±³À°ÁÖÁ¦ : (ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ
ÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ
¿¬¶ôó : 02-735-2857  
À̸ÞÀÏ : meetings@ksmo.or.kr      
±³À°Á¾·ù : ³»°ú¾à¸®ÇÐ, ÀÇ·áÄ¿¹Â´ÏÄÉÀ̼Ç, ÀÇ·áÁ¤Ã¥
Âü¼®¿¹»óÀοø : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 10ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í »çÀüµî·Ï- ȸ¿ø : 40,000, ÁØȸ¿ø : 30,000, 65¼¼ ÀÌ»ó : ¹«·á -ºñȸ¿ø ±³¼ö, Àü¹®ÀÇ ¹Ú»ç±Þ ¿¬±¸¿ø : 50,000ÀüÀÓÀÇ, Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 30,000ÇöÀåµî·Ï- ȸ¿ø : 60,000, ÁØȸ¿ø :50,000, 65¼¼ ÀÌ»ó : ¹«·á - ºñȸ¿ø±³¼ö, Àü¹®ÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø : 70,000ÀüÀÓÀÇ,Àü°øÀÇ, °£È£»ç, ¾à»ç, ±ºÀÇ°ü, Çлý : 50,000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 09:00~09:40 Cost and value in cancer care  Leonard Saltz(MSKCC) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 09:40~10:00 One step back to move forward for KSMO  ±èÅ¿ø(¼­¿ï¾Æ»êº´¿ø) 
±âŸ 05-20 Crystal Ballroom A (2F) 10:00~10:10 KSMO ¹Ì¼Ç/ºñÀü/Çٽɰ¡Ä¡ ¼±Æ÷½Ä  () 
È޽Ġ05-20 Crystal Ballroom A (2F) 10:10~10:20 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:20~10:35 Progress in precision oncology : KPMNG report  ±èÅ¿ë(¼­¿ï´ëº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:35~10:55 Challenges to harmonize Molecular Tumor Board decision – case sharing from KOSMOS study   À̼¼ÈÆ(»ï¼º¼­¿ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 10:55~11:10 Implementing NGS and MTB guideline in clinical practice  À±½Å±³(¼­¿ï¾Æ»êº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 11:10~11:30 Lessons learned from Precision oncology clinical trials and suggestions for the future studies   ÃÖÀ±Áö(°í´ë¾È¾Ïº´¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 11:30~11:40 Discussion  () 
È޽Ġ05-20 Crystal Ballroom A (2F) 11:40~11:50 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 11:50~12:30 ±è³ë°æ»ó ½Ã»ó ¹× °­¿¬  ±è¿­È«(°í´ë¾È¾Ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 12:30~13:10 Rozlytrek: Leading a new era in Personalized Healthcare  Á¶º´Ã¶(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 13:10~13:25 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ¾Ï ´ÙÇÐÁ¦ Á¦µµ  È²ÀαÔ(Á߾Ӵ뺴¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 13:25~13:35 Discussion  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 13:35~13:50 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ÀûÁ¤¼º Æò°¡ Á¦µµ  °íÀ±È£(ÀºÆò¼º¸ðº´¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 13:50~14:00 Discussion  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:00~14:15 Á¾¾ç³»°ú Àǻ簡 ¾Ë¾Æ¾ß ÇÒ ÁöºÒÁ¦µµ  Á¤ÁÖ¿µ(ÇѸ²´ëµ¿Åº¼º½Éº´¿ø) 
Åä·Ð 05-20 Crystal Ballroom A (2F) 14:15~14:25 Discussion  () 
Åä·Ð 05-20 Crystal Ballroom A (2F) 14:25~14:30 ÁÂÀå Á¤¸® ÅäÀÇ  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:30~14:40 2021³â º¸ÇèÁ¤Ã¥¿¬±¸ºñ»ó ¿¬±¸ ¹ßÇ¥  ¿ø¿µ¿õ(ÇѾç´ë±¸¸®º´¿ø) 
È޽Ġ05-20 Crystal Ballroom A (2F) 14:40~14:50 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 14:50~15:10 Identification of Resistance Mechanisms: Immune Checkpoint Therapy  ¹ÚÁöÇö(°Ç±¹´ëº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:10~15:30 Single cell genomics approach to identify immune determinants for PD-1 inhibitors  ±èÇý·Ã(¿¬¼¼¾Ïº´¿ø) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:30~15:50 T cell Exhaustion and Relevance for Immunotherapy of Cancer:  ¹Ú¼öÇü(KAIST) 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 15:50~16:10 The Evolving Landscape of Immunotherapy  ÀÌ´ëÈ£(¼­¿ï¾Æ»êº´¿ø) 
È޽Ġ05-20 Crystal Ballroom A (2F) 16:10~16:20 Break  () 
±³À°½Ã°£ 05-20 Crystal Ballroom A (2F) 16:20~17:00 Circulating tumor DNA to direct therapy for cancer  Nicholas turner(The Institute of Cancer Research) 
±âŸ 05-20 Crystal Ballroom A (2F) 17:00~17:30 Á¤±âÃÑȸ & Awards  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (ÇÏÀ̺긮µå)2022³â ´ëÇÑÁ¾¾ç³»°úÇÐȸ Á¦20Â÷ Á¤±â ½ÉÆ÷Áö¿ò ¹× ÃÑȸ : 2022-05-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2022 ´ëÇѳ»½Ã°æ³ú¼ö¼úÇÐȸ Á¦6ȸ Á¤±âÇмú´ëȸ : 2022-05-20
´ÙÀ½±Û Á¦50Â÷ ´ëÇѼҾƳ»ºÐºñÇÐȸ Ãá°èÇмú´ëȸ : 2022-05-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 15 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 10 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 14 2024-05-28
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 12 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 31 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 121 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 42 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 120 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 34 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 23 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 22 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 44 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 13 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 21 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 12 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷